(0.32%) 5 116.41 points
(0.30%) 38 354 points
(0.37%) 15 988 points
(-0.98%) $83.03
(5.25%) $2.02
(0.29%) $2 353.90
(0.39%) $27.64
(4.16%) $960.45
(-0.27%) $0.932
(-0.45%) $10.98
(-0.57%) $0.796
(1.63%) $93.37
@ $125.59
発行日: 30 4月 2024 @ 01:08
リターン: -0.37%
前回のシグナル: 4月 29 - 23:49
前回のシグナル:
リターン: 1.93 %
Live Chart Being Loaded With Signals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally...
Stats | |
---|---|
本日の出来高 | 1.64M |
平均出来高 | 3.18M |
時価総額 | 49.55B |
EPS | $0 ( 2024-04-25 ) |
次の収益日 | ( $0.390 ) 2024-07-25 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 81.25 |
ATR14 | $5.44 (4.35%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Dolan Matthew Vincent | Sell | 1 990 | Common Stock |
2024-04-08 | Sayer Kevin R | Sell | 27 272 | Common Stock |
2024-04-08 | Sayer Kevin R | Sell | 22 361 | Common Stock |
2024-03-28 | Brown Michael Jon | Sell | 2 524 | Common Stock |
2024-03-28 | Brown Michael Jon | Sell | 100 | Common Stock |
INSIDER POWER |
---|
-3.99 |
Last 99 transactions |
Buy: 330 077 | Sell: 354 468 |
ボリューム 相関
DexCom Inc 相関 - 通貨/商品
DexCom Inc 財務諸表
Annual | 2023 |
収益: | $3.62B |
総利益: | $2.29B (63.19 %) |
EPS: | $1.400 |
FY | 2023 |
収益: | $3.62B |
総利益: | $2.29B (63.19 %) |
EPS: | $1.400 |
FY | 2022 |
収益: | $2.91B |
総利益: | $1.88B (64.72 %) |
EPS: | $0.880 |
FY | 2021 |
収益: | $2.45B |
総利益: | $1.68B (68.63 %) |
EPS: | $0.400 |
Financial Reports:
No articles found.
DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。